Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients

This is a double-blind, randomized controlled study evaluating the efficacy and safety of HGXJT in combination with ICI-based standard treatment in lung cancer patients with bone metastases. Enrolled participates will randomly receive HGXJT or placebo during the first 4-6 cycles of ICI-based standard treatment.

NCT Number	NCT05378334
Lead Sponsor	Guangzhou University of Traditional Chinese Medicine
Conditions	Non-small Cell Lung Cancer
Enrollment	82 participants
Start Date	2022-06-15
Primary Completion	2027-09-01 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-10